Robert P. Bianchi

Mr. Bianchi is currently the President and Chief of Scientific and Technical Affairs at the Prescription Drug Research Center, Bradenton, FL.  He retired as a laboratory director for the Drug Enforcement Administration after 34 years of federal service, where he held increasingly responsible positions as an analytical chemist for the FDA and DEA to the chief of DEA's Laboratory Operations Section.  Mr. Bianchi was also director of the DEA Special Testing and Research Laboratory where extractability experiments were conducted more than twenty years ago.
       Since 2005 he has been working with the pharmaceutical industry and FDA on developing in vitro protocols to evaluate abuse deterrent formulations and has been actively involved is sharing his experience with the regulatory, treatment, pharmaceutical abuse and law enforcement community. For the last decade, he has participated dozens of category 1 studies on abuse-deterrent opioid formulations, appeared as a panelist and presenter at abuse deterrent formulation & prescription drug abuse professional meetings. Mr. Bianchi has provided drug related consultations to more than thirty organizations/companies concerned about OTC & prescription drug abuse and has made numerous presentations to the regulatory, treatment, pharmaceutical, abuse and law enforcement communities. He has also presented in vitro laboratory data to the FDA Advisory Committee for a new immediate release oxycontin formulation.
       Mr. Bianchi is also a Special Government Employee for participation in the FDA Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee meetings.